Researchers See Silver Lining in Anti-HIV Gel’s Failure

“I am anxious not to confuse the results of our trial with [the tenofovir trial]. PRO2000 is much less potent than tenofovir,” Dr. McCormack said. “You’ve got to think about this in a bigger picture: At the moment, there’s a real possibility in tenofovir gel.”

Dr. McCormack’s study was funded by the U.K. government, the European and Developing Countries Clinical Trials Partnership, the International Partnership for Microbicides, and Endo Pharmaceuticals, the manufacturer of PRO2000, which donated the gels for the study. One coauthor of the study was an employee of Endo Pharmaceuticals with an equity interest in the company.